Levy, Carol J.Foster, Nicole C.DuBose, Stephanie N.Agarwal, ShivaniLyons, Sarah K.Peters, Anne L.Uwaifo, Gabriel I.DiMeglio, Linda A.Sherr, Jennifer L.Polsky, Sarit2024-04-232024-04-232021Levy CJ, Foster NC, DuBose SN, et al. Changes in Device Uptake and Glycemic Control Among Pregnant Women With Type 1 Diabetes: Data From the T1D Exchange. J Diabetes Sci Technol. 2021;15(6):1297-1302. doi:10.1177/1932296820972123https://hdl.handle.net/1805/40141Objectives: To examine changes in device use and glycemic outcomes for pregnant women from the T1D Exchange Clinic Registry between the years 2010-2013 and 2016-2018. Methods: Participant-reported device use and glycemic outcomes were compared for women aged 16-40 years who were pregnant at the time of survey completion, comparing 2010-2013 (cohort 1) and 2016-2018 (cohort 2). Hemoglobin A1c results within 30 days prior to survey completion were obtained from medical records. Results: There were 208 pregnant women out of 5,236 eligible participants completing the questionnaire in cohort 1 and 47 pregnant women out of 2,818 eligible participants completing the questionaire in cohort 2. Continuous glucose monitor (CGM) use while pregnant trended upward among cohort 2 (70% vs 37%, P = .02), while reported continuous subcutaneous insulin infusion (CSII) use while pregnant declined (76% vs 64%, P = .04). HbA1c levels trended downward (6.8% cohort 1 vs 6.5% cohort 2, P = .07). Conclusions: Self-reported CGM use while pregnant increased over the studied intervals whereas CSII use decreased. Additional evaluation of device use and the potential benefits for T1D pregnancies is needed.en-USPublisher PolicyContinuous glucose monitorFemalePregnancyType 1 diabetesArticle